Endocyte, Inc., … presented data from a Phase 2a clinical trial for EC145, … In 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant pe… more →
Libby's H*O*P*E*wrote 2 months ago: Endocyte, Inc., … presented data from a Phase 2a clinical trial for EC145, … In 49 women … more →
wrote 8 months ago: Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat. … more →
wrote 10 months ago: “… ACCESS PHARMACEUTICALS, INC. … , announced today positive safety and efficacy r … more →
wrote 1 year ago: I don’t want this blog to become a political footstool, but I saw this video this morning and … more →